In order to characterize the role of SMYD3 in the expression of c-MYC-related CRC-SC markers, we treated patient-derived CRC-SCs with two different SMYD3 pharmacological inhibitors, the previously characterized substrate-competitive inhibitor BCI-12126 and the covalent inhibitor EM127. Here, SMYD3 is linked to colorectal carcinoma.